Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 4.63% | 0.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.63% | 0.67% | |||
| Cost of Revenue | 11.68% | 7.20% | |||
| Gross Profit | 3.09% | -0.65% | |||
| SG&A Expenses | 10.16% | -12.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -87.14% | 91.07% | |||
| Total Operating Expenses | 11.51% | 1.65% | |||
| Operating Income | -19.70% | -2.65% | |||
| Income Before Tax | -45.70% | -20.88% | |||
| Income Tax Expenses | -122.63% | 2.24% | |||
| Earnings from Continuing Operations | -30.41% | -24.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 125.00% | -100.00% | |||
| Net Income | -30.13% | -24.42% | |||
| EBIT | -19.70% | -2.65% | |||
| EBITDA | -22.16% | -1.83% | |||
| EPS Basic | -30.12% | -24.38% | |||
| Normalized Basic EPS | -21.94% | -0.21% | |||
| EPS Diluted | -30.17% | -24.79% | |||
| Normalized Diluted EPS | -21.99% | -0.28% | |||
| Average Basic Shares Outstanding | 0.00% | -0.06% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.00% | |||
| Dividend Per Share | -- | -100.00% | |||
| Payout Ratio | -1.00% | 83.80% | |||